Upper Respiratory Symptoms, Gut Health and Mucosal Immunity in Athletes

Candice Colbey1 · Amanda J. Cox1 · David B. Pyne1,2,3 · Ping Zhang1 · Allan W. Cripps1 · Nicholas P. West1

Abstract Upper respiratory symptoms remain the most common illness in athletes. Upper respiratory symptoms during heavy training and competition may impair performance. Preventing illness is the primary reason for the use of supplements, such as probiotics and prebiotics, for maintaining or promoting gut health and immune function. While exercise-induced perturbations in the immune system may increase susceptibility to illness and infection, growing evidence indicates that upper respiratory symptoms are related to a breakdown in the homeostatic regulation of the mucosal immune system of the airways. Balancing protection of the respiratory tract with normal physiological functioning requires dynamic orchestration between a wide array of immune parameters. The intestinal microbiota regulates extra-intestinal immunity via the common mucosal immune system and new evidence implicates the microbiota of the nose, mouth and respiratory tract in upper respiratory symptoms. Omics’ approaches now facilitate comprehensive profiling at the molecular and proteomic levels to reveal new pathways and molecules of immune regulation. New targets may provide for personalised nutritional and training interventions to maintain athlete health.

1 Introduction

With the exception of injury, the most common medical presentation in elite athletes [1–3] is upper respiratory symptoms (URS). While the frequency of infectious URS in athletes is comparable to the general population, the timing does not follow typical seasonal fluctuations [4]. This pattern indicates that factors specific to the type of exercise and athlete behaviour can alter susceptibility to URS, particularly as episodes appear more frequently during periods of increased training load and around competition [5]. Successful competitive performance for an elite athlete is often determined by the narrowest of margins. Upper respiratory symptoms may have a range of detrimental effects on athletic performance, including reduced aerobic capacity, muscular strength, muscular coordination, speed of contraction, alertness and information processing [6–8].

While anecdotally the issue of URS is of high concern to athletes and coaches, few studies have directly quantified the effects of URS on performance outcomes. A study of elite swimmers indicated that mild illness had only trivial effects on the performance of female swimmers and a small harmful effect in male swimmers [9]. Mild URS did not impair submaximal and maximal performance in highly trained middle- and long-distance runners [10]. Many factors contribute to increased URS in elite athletes including travel, stress, low energy availability and poor sleep quality (Fig. 1) [11].

Acute and chronic exercise-induced perturbations of the mucosal immune system may be a factor in the patterns of URS in athletes. The mucosal immune system, including the airway epithelia and microbiota, is an integrated network of mechanical, cellular and humoral factors balanced to protect the host from environmental antigens.

1 Menzies Health Institute Queensland and School of Medical Science, Griffith University, Griffith Health Gold Coast Campus, Southport, QLD 4222, Australia
2 Faculty of Health, University of Canberra Research Institute for Sport and Exercise, University of Canberra, Canberra, ACT, Australia
3 Discipline of Physiology, Australian Institute of Sport, Canberra, ACT, Australia
while maintaining homeostasis. The importance of host microbiota in the regulation of the mucosal immune system has driven athlete interest in the use of nutritional strategies to maintain gut health. This review examines mucosal immunity, the microbiota and gut-respiratory axis and use of a systems biology approach in the context of URS and athlete health. We also consider the implications of this approach for personalised nutrition and intervention approaches to minimise URS in athletes.

2 Upper Respiratory Symptoms in Athletes

Upper respiratory symptoms involve several non-specific symptoms of the upper airways including coughing, sneezing, congestion, sore throat, mucus production and bronchoconstriction [12]. Upper respiratory symptoms are thought to impair athletic performance, with athletes and coaches placing a high priority on preventing illness [13]. A recent study in elite athletes preparing for the Rio 2016 Olympics revealed a broad list of risk factors for URS, including sex, energy availability, stress, communal living and hygiene practices associated with increased URS [14]. Improved knowledge regarding these factors will enhance the monitoring, management and application of intervention strategies needed to maintain athlete health and maximise competitive sporting outcomes.

The frequency of URS is higher during prolonged intense training or in acute periods of increased training and competition [15]. Training history and fitness may provide a higher tolerance to high training loads and a lower risk of URS [16]. Epidemiological and observational evidence indicates immune perturbations associated with URS occur more strongly in response to endurance exercise, such as marathon running, swimming and triathlon, than in team sports [17]. Seminal research in the area of exercise and URS noted that marathon runners with higher training loads had an almost a two-fold greater risk of URS than with low training loads. Completion of a marathon led to a six-fold increase in the likelihood of URS than in runners who had trained but did not compete [18, 19]. Similar reports are also available in other sports. A 2-week intensified training period increased URS almost threefold in well-trained male cyclists [20]. A large body of evidence now supports the premise that prolonged periods of intense exercise training can increase susceptibility to URS.

3 Aetiology of Upper Respiratory Symptoms

Infectious pathogens, in particular viruses, are considered the primary cause for URS in athletes. Interestingly though, a study of 32 elite triathletes, 31 recreational triathletes and 20 sedentary non-athletes, which monitored URS over 5 months, reported that out of 37 episodes of illness, only 30% were caused by an infectious agent [21]. Furthermore, a prospective 14-month analysis of URS in 70 elite athletes in several sports could not identify a bacterial or viral pathogen in 43% of episodes [22]. Cox et al. [22] demonstrated that in elite athletes only 57% of clinician-diagnosed upper respiratory infections were found to be of infectious aetiology. Although laboratory identification of pathogens has sample and methodological limitations [23], evidence from these moderately sized athletic cohorts is suggestive of URS having multiple aetiologies. One theory is that URS can be induced by increased exposure to aeroallergens that generate a hypersensitivity response [24]. Another possible explanation for URS is exercise-induced bronchoconstriction [25]. Exercise-induced bronchoconstriction is considered a consequence of airway drying related to hyperventilation that initiates an acute inflammatory response of the upper airways [26]. Exercise-induced bronchoconstriction is commonly reported in athletes with asthma and may relate to disease control [26, 27]. Despite differences in aetiology, whether infection, allergy or generalised inflammation, URS presents with similar signs and symptoms and has common effects on human performance. Given the uncertainty regarding the aetiology of respiratory symptoms in athletes, there are recommendations that symptoms be reported as URS instead of upper respiratory tract illness or infection (URTI) [28].

4 Mucosal Immunity and Respiratory Illness

The clinical need for a differential diagnosis of URS in athletes has led to an increasing focus on the mechanisms of mucosal homeostasis in the respiratory tract. The
mucosal epithelial/immune system, referred to hereon as the mucosal immune system, lines the external surfaces of the body. As the interface with the environment, the mucosal immune system orchestrates a delicate balance between protection of the body from external antigens and maintenance of homeostasis for normal physiological functioning [29]. To maintain this balance, the mucosal immune system has specialised effector and regulatory mechanisms to neutralise, remove and promote tolerance to antigens without inducing an inflammatory response (Fig. 2). While not separate from the systemic immune system, the localised defence factors and regional regulation of inflammatory processes at the mucosa [30] mean the mucosal immune system is often considered independent from other immune processes in the body.

A breakdown in several mechanisms of the airways may be involved in URS. The airway epithelia of the nose and throat are constantly exposed to external antigens and consist of several cell types that each play a different role in facilitating protection of the respiratory tract [31]. The airway epithelium regulates the secretion of saliva and composition of its constituent components, including mucus, secretory immunoglobulin A (SIgA), and humoral innate immune proteins, such as lactoferrin, lysozyme, and the defensins. Together with the epithelium, saliva and its various constituents form a physical and chemical barrier to prevent chronic inflammatory processes occurring in response to the constant exposure of antigenic material passing through the respiratory tract. The airway epithelium, in combination with localised antigen-presenting cells, links the innate and adaptive immune system via production of cytokines and chemokines to initiate inflammation should infection occur. However, the respiratory tract contains specialised lymphoid cells and immune mechanisms to exert an immunosuppressive influence on adaptive immune processes to tightly control inflammatory responses.

Important differences between airway and systemic immune compartments are being identified that provide insights into the aetiology of airway illness. A recent analysis of cluster of differentiation (CD)4+ T cell subsets in the human upper airway mucosa under non-inflammatory conditions reported that regulatory T-cells (T-regs) secreted substantially higher quantities of interleukin (IL)-10 than T-regs in peripheral blood [32]. Interleukin-10 is an immunoregulatory cytokine that exerts a suppressive influence on inflammatory responses and is central to resolving inflammation. Interestingly, this study also

Fig. 2 Schematic of the mucosal immune system. Interaction with environmental antigens a the microbiota, microbial metabolites, antimicrobial proteins (AMPs) (c) and dendritic processes b provide the mucosal immune system with multiple transient activation signals. Antigen invasion is prevented by the mucus layer, its constituent components and ciliated airway cells. T- and B-cell subsets d provide multiple, but highly plastic cell differentiation programmes. CD cluster of differentiation cells, Th T-helper, IgA immunoglobulin A, II interleukin, NF-kB nuclear factor-kappa B, TGF-β transforming growth factor beta, TLR toll-like receptor, T-regs regulatory T cells

© Springer
observed that inducible T-regs (foxp3+/helios−) in the airways contained the highest frequency of IL-17-producing cells of the CD4+ T-cell subsets and that a higher percentage of foxp3 CD4+ T cells produced IL-10 than peripheral blood [32]. The higher frequency of inducible T-regs producing IL-17 may be important for the transport of S IgA through the induction of T-helper (Th)-17 cells required for T-cell-dependent immunoglobulin A production [33]. In recent years, recognition of the role of innate lymphoid cells as regulators of the mucosal immune system has been confirmed [34]. Immunological processes in the airway mucosal immune system exert an immunosuppressive influence to maintain homeostasis. A better understanding of these specific processes, particularly under exercising conditions, is required if strategies are to be developed to limit URS in athletes.

Dysfunction of the mucosal immune system is associated with increased illness, including URS. The lack of infectious sequelae in the URS of athletic groups has led to interest in whether dysregulated inflammatory processes underpin the patterns of illness observed [4]. Hypersensitivity reactions, such as asthma and allergy, are increasing in prevalence in the general population. Undiagnosed allergy and asthma are recognised as an additional cause of unexplained URS in athletes and the need for appropriate diagnosis and management is deemed a priority [4]. However, factors specific to elite athletes and sports modalities may also induce transient, non-allergic, asthma-like airway inflammation. Damage to the airway lining from hyperventilation via breathing through the mouth or from unfavourable conditions (cold or polluted air) is recognised as a cause of airway problems in athletes [35].

Evidence from animal research suggests that epithelial damage-related chemokines may mediate non-allergic asthma-like inflammation in the airways through type 2 innate lymphoid cells (ILC2s) in the absence of adaptive Th-2-driven immunity [36]. Type 2 innate lymphoid cells are immune cells phenotypically similar to Th-2 lymphocytes that lack antigen receptors and secrete IL-4, IL-5, IL-9 and IL-13. Type 2 innate lymphoid cells respond to airway epithelial-derived cytokines, such as IL-25, IL-33 and thymic stromal lymphopoietin [37], to initiate a type 2 inflammatory event (asthma-like) in the respiratory tract. Activation of ILC2s in the respiratory tract has been linked with allergic and non-allergic asthma-like airway inflammation in animal models. In rag2−/−IL2r−/− mice that lack lymphocytes (including ILC2s), administration of epithelium-derived IL-33 via inhalation does not induce asthma-like inflammation. However, an asthma-like response can be partially induced by engraftment of ILC2s in the respiratory epithelia [36]. Evidence that ILC2s mediate non-allergic asthma-like symptoms in response to airway epithelial damage provides a mechanism that may explain the idiopathic symptomatology being described as URS in athletes.

In general, athlete-related URS are considered to be local to immune mechanisms in the respiratory tract rather than from exercise-induced systemic inflammatory processes, which has implications for using systemic markers as a surrogate measure of URS risk. While studies have examined numerous systemic and mucosal cellular [38] and humoural [39, 40] immune parameters in the context of risk of URS in athletes, only S IgA has shown moderate diagnostic value [41], although its utility is limited given large intra- and inter-individual variation [42]. The role of other humoural factors in saliva is also becoming apparent with micro-proteomic technology. The application of microproteomic technology using the saliva of healthy individuals identified over 1000 secreted proteins, while a comparison of the proteins in saliva between patients with influenza and healthy controls identified 162 differentially expressed proteins associated with the respiratory mucosal immune response [43]. Research in non-athletic cohorts has also failed to identify systemic inflammatory markers with strong diagnostic value for respiratory infection, even within cohorts admitted to hospital [44]. Animal and human research provides some evidence that inflammatory cytokines associated with excess body mass, such as IL-1β, may exacerbate ILC2 and ILC3 airway responses [45], indicating that systemically released serum cytokines could modulate airway responses to harmful and innocuous stimuli. Whether this process relates only to secretions from adipose tissue and not muscle-derived cytokines from exercise is yet to be established.

Biological factors may also limit the utility of using systemic markers as a surrogate for mucosal immune processes that underpin URS [46]. Mucosal compartments contain site-specific immune cells that govern cell receptor repertoires and functions. Exercise is recognised to induce changes in the frequencies of systemic cell populations, in particular T-regs [47, 48]. These changes in the frequency of systemic cell populations are linked to the beneficial anti-inflammatory effects of exercise but could mediate the increased susceptibility to URS in some athletes [49, 50]. Interestingly, investigations in patients with inflammatory bowel disease found no correlation between changes in the percentage of peripheral CD4+CD25hiFOXP3+ T-regs and intestinal FOXP3+ T-regs with clinical activity [51], suggesting that changes in the frequency of T-regs in blood may be independent of those in the mucosa.

Furthermore, the continued identification in the mucosal immune system of new rare lymphocyte subsets and subsets that co-express lineage-specific transcription factors and chemokine receptors is re-defining the traditional view of adaptive immunity as being either a Th-1- or Th-2-driven response [52]. There appears to be far greater
phenotypic plasticity amongst CD4+ T-cell subsets, greater overlap between subsets than previously recognised, and striking differences between sites in cell composition and function, particularly in relation to the airway [53, 54]. Whether immune cells in peripheral blood reflect the frequency and function of immune cells in the airways is yet to be established. Taking account of the complexity of the mucosal immune network will be necessary before changes in susceptibility to URS can be determined via peripheral markers.

5 Microbiota, Nutrition Supplements and Upper Respiratory Symptoms

Interest in the microbiome has grown in recent decades with strong evidence that host microbes are essential for the ontogeny of the immune system and play a central role in health and disease. To date, the major focus has been on gut bacteria, now estimated to number ~10^{14} colony-forming units across 500 species. The intestinal microbiota is involved in the vital functions of food digestion, nutrient production, priming of the immune system, protection from ingested pathogens and production of short-chain fatty acids [55, 56]. Host microbes are proposed to exist in a continuum from symbiosis in healthy individuals to dysbiosis in disease. Basic and human research has implicated the intestinal microbiota in intestinal diseases, such as inflammatory bowel disease and colon cancer, along with extra-intestinal diseases including obesity and metabolic syndrome [57]. The profound influence of the microbiota in health and disease has led to the funding of large-scale collaborative and international consortia [58, 59] to catalogue an ecosystem that is now considered an organ system in its own right.

The intestinal microbiota is able to alter homeostasis at distant mucosal sites, including the respiratory tract, through the common mucosal immune system [60]. Existence of the common mucosal immune system has long been accepted through evidence that vaccination elicits protection at (mucosal) sites distal to the initial mucosal site of immunisation [61]. A key mechanism of microbial influence on distant mucosal sites from the intestine is through induction of immunoglobulin A-producing plasma cells [62]. Luminal sampling of host microbiota by dendritic cells in the intestinal mucosa is considered a key aspect of host-microbe signalling [63]. Antigen-primed B cells migrate via the thoracic duct throughout the mucosa and differentiate into plasma cells. At these sites, plasma cells produce SIgA that is transported to mucosal surfaces to act as a primary molecule in immune exclusion of environmental antigens [64]. Animal and human studies demonstrate the production of antigen-specific SIgA occurs in the intestine and respiratory tract in parallel [65]. The intestinal microbiota is also implicated in the maintenance and differentiation of T-cell subsets located in distal mucosal sites [66]. Animal research highlights that specific clusters of Clostridia promote the accumulation of T-regs in the intestine [67]. More recently, the microbiota has also been found to promote T-regs that express the Th-17 phenotype that, in conjunction with T-regs, regulate homeostasis in the mucosa [68]. There is strong evidence that the intestinal microbiota plays a key role in programming of the mucosal immune system.

There is strong interest in gut health and the host microbiota for athlete health yet a paucity of experimental research in athletes. A recent study reported that regular moderate physical activity improved anxiety, SIgA and total culturable oral bacteria counts in 19 female athletes [69]. While this outcome suggests a positive effect of moderate exercise on oral microbial diversity, no mention is made of dietary profiling of the athletes, and molecular methods would provide a more detailed understanding of bacterial diversity given many species cannot be cultured. Only one study has examined intestinal bacteria in elite athletes, a comparison between a professional international-level rugby team (n = 40) with a non-rugby-playing, healthy, low body mass index (BMI) (22 ± 1.8 kg/m²; mean ± standard deviation) and a healthy high BMI (31.2 ± 3.0 kg/m²) cohort. The inclusion of a healthy high BMI group provided a direct comparison of the microbiota with BMI, which has been shown to have lower diversity in individuals with high BMI [70]. The study found a higher microbial diversity in the rugby players that appeared to relate to the dietary intake of the athletes, with the athletes consuming more total calories and higher amounts of all macronutrients [71].

The outcomes in the rugby players are consistent with work in our laboratory, with national-level triathletes having a greater diversity of intestinal microbiota than non-athletic healthy individuals (unpublished data). Diet has a profound effect on the intestinal microbiota [72] and is proposed to be the primary reason that the microbiota may be more diverse in athletes [73]. However, a recent study in 39 healthy active adults controlled for age, BMI and diet found that cardiorespiratory fitness was positively correlated with the diversity of the gut microbiota [74]. This has important implications for exercise prescription and potentially for decisions by athletes on a sport-by-sport basis for the use of gut health supplements. As yet, there is little information on whether athletes who are more susceptible to URS differ in the diversity of intestinal or oral microbiota compared to healthy athletes.

The influence of the intestinal microbiota on respiratory health underpins the interest by athletes in the use of gut health products, such as probiotics and prebiotics, to reduce susceptibility to URS. Evidence on the effectiveness of
probiotics in athletic groups is mixed (Table 1), with some studies showing a reduction in the rate of URS while other studies report a reduction in the duration or severity of illness but no effect on incidence [75, 76]. Differences in the effectiveness of probiotic supplements relate to the type of sport (endurance vs. team sport), the training history of the athlete, the training load being undertaken along with supplement-specific differences in the strain(s), method of delivery and duration of supplementation [77].

Research in our group has also observed sex differences in the effect of probiotic supplementation on URS. In this study of 99 competitive cyclists (64 male and 35 female individuals; age 35 ± 9 and 36 ± 9 years), respiratory symptoms were lower by a factor of 0.31 [99% confidence interval (CI) 0.07–0.96] in male individuals but increased by a factor of 2.2 (99% CI 0.41–27) in female individuals during 11 weeks of supplementation with *Lactobacillus fermentum* (PCC®) [78]. The mechanisms underpinning the beneficial effects of probiotic supplements on URS may include modulation of serum cytokines and SIgA, and changes in the percentage and functional capability of innate and adaptive immune cells [76, 79]. Animal and in vitro studies also show that probiotic strains can increase the expression of mucin genes and mucin secretion from intestinal epithelial cells along with secretion of antimicrobial peptides, which would enhance the barrier function of the mucosa [80]. At this stage, various immune mechanisms may explain the beneficial effects of probiotics on URS in athletes.

Few studies have examined the effects of prebiotics on URS and the immune system in athletes. The effects of β-glucan, a long-chain non-digestible carbohydrate, on URS and the immune system have been examined in acute exercise extended training (10–90 days) with mixed outcomes. The administration of β-glucan for 28 days in 182 healthy adults before a marathon was associated with a significant 37% reduction in the number of URS symptom days compared with placebo [81]. This study also reported that 10 days of β-glucan supplementation prior to a 60-min cycling session in a hot (45 °C) and humid (~ 50% humidity) environment was associated with a 32% increase in SIgA 2 h post-exercise in 60 healthy active individuals [81]. A longer duration supplement period of 90 days in 50 athletes in a placebo controlled trial also reduced the

### Table 1 Effect of probiotic supplementation on upper respiratory symptoms (URS) in athletic cohorts ranging from healthy active individuals through to elite athletes

| References                  | Study design and participants                                                                 | Intervention                                                                 | Impact on URS                                                                 |
|-----------------------------|-----------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------|-------------------------------------------------------------------------------|
| Clancy et al. [119]         | Double-blind placebo-controlled trial of 18 healthy and nine fatigued recreational athletes over 4 weeks | Probiotic (*Lactobacillus acidophilus* LAFT1-L10 strain) daily                | Reversal of defect in IFN-γ secretion from T cells (viral control mechanism) |
| Cox et al. [120]            | Double-blind placebo-controlled trial of 20 healthy, elite male distance runners over 16 weeks | Probiotic (*Lactobacillus fermentum* VRI-003 strain) daily                    | Reduced incidence of URS by 50% and reduced severity of symptoms and trend for higher IFN-γ secretion from T cells (*p = 0.07*) |
| Gleeson et al. [79]         | Double-blind placebo-controlled trial of 84 endurance athletes over 16 weeks                 | Probiotic (*Lactobacillus casei* Shirata strain) daily                        | Reduced the number of URS episodes by ~ 50%; higher SIgA level in those taking probiotics |
| Haywood et al. [86]         | Single-blind, placebo-controlled, double-arm crossover trial of 30 rugby players, 4 weeks per treatment separated by a 4-week washout | Probiotic (*Lactobacillus gasseri, Bifidobacterium longum, Bifidobacterium bifidum strains*) daily | No difference in the incidence of URS                                         |
| West et al. [87]            | Double-blind placebo-controlled trial of 88 well-trained recreational cyclists over 11 weeks  | Probiotic (*Lactobacillus fermentum* VRI-003 strain) daily                    | No significant effects on URS; reduction of LRI in male cyclists by a factor of 0.31 but a 2.2-fold increase in LRI in female cyclists |
| Gleeson et al. [76]         | Double-blind placebo-controlled trial of 54 endurance athletes over 16 weeks                 | Probiotic (*Lactobacillus salivarius* strain) daily                          | No difference in the incidence of URS                                         |
| Kekkonen et al. [75]        | Double-blind placebo-controlled trial of 141 marathon runners over 3 months                 | Probiotic (*Lactobacillus rhamnosus* GG strain) daily                        | No difference in the incidence of URS                                         |
| West et al. [88]            | Double-blind placebo-controlled trial of 465 physically active individuals for 150 days     | Probiotics (*Bifidobacterium animalis* subsp. *lactis* Bi-04) daily or *Lactobacillus acidophilus* NCFM and *Bifidobacterium animalis* subsp. *lactis* Bi-07 daily | BL-04 associated with a significant 27% reduction in the risk of URS compared with placebo |

*IFN* interferon, *LRI* lower respiratory illness, *SIgA* salivary immunoglobulin A
incidence of URTI and increased the number of circulating natural killer cells [82].

In contrast to these studies, consumption of β-glucan for 2 weeks before, during and 1 day after 3 days of exercise in which athletes cycled for 3 h per day at 57% of their maximal wattage had no significant effect on URTI in the 2 weeks post-exercise [83]. Research by our group examining 28 days of butyrylated high-amylose maize starch supplementation in 41 recreational cyclists observed significant increases in faecal short chain fatty acids, the abundance of faecal Parabacteroides distasonis and Faecalibacterium prausnitzii, and in the concentration of plasma IL-10 and tumour necrosis factor-α [84]. Faecalibacterium prausnitzii is recognised for a range of important mucosal and systemic anti-inflammatory effects and for promoting gut health [85]. Beneficial effects of prebiotics and probiotics have been shown for a variety of sports, including team sports [86], highly active elite triathletes along with recreational endurance athletes [76, 79, 87], and healthy active individuals undertaking general exercise, team sports and endurance sports [88].

The use of colostrum for gut health and immune function has also been extensively studied in athletes. Colostrum is rich in antibodies and growth factors, which may be protective by modulating the gut microbiota and improving intestinal permeability. A focus of research using colostrum supplementation has been to prevent heat-related exercise-induced intestinal permeability albeit with mixed results [89, 90]. In one study, supplementation with bovine colostrum during 8 weeks of endurance running training increased intestinal permeability compared with whey protein powder [91]. A recent meta-analysis on the use of bovine colostrum for URS during exercise indicated that supplementation reduced the incidence rate of URS days (rate ratio 0.56, 95% CI 0.43–0.72) and URS episodes (0.62, 95% CI 0.40–0.99) [92]. While evidence suggests limited effects on gut and immune markers [93], the reduction in URS highlights the potential for colostrum forming one part of a strategy to maintain health in athletes.

More recently, the contribution of the oral microbiome in respiratory illness has generated significant interest. Overall, there is considerable diversity within the oral microbiome [94]. A comparison of the microbe-specific peptide composition of saliva quantified more than 2000 microbial proteins from 50 bacteria genera, with significant differences in the proteins and species between individuals and in response to food consumption and cleaning teeth [95]. Differences in the composition of the oral microbiome have also been observed in individuals with severe asthma, who had higher numbers of microbes associated with eosinophilia compared with healthy controls and individuals without severe asthma [96]. Interestingly, a reduction in the diversity of the oral microbiome has been observed in oral and respiratory disease, which is similar to observations regarding the intestinal microbiota and intestinal disease [97]. Whether this is causal is yet to be determined. A comparison in 28 healthy individuals of the microbiome of the upper airways also revealed significant differences in the composition of the nasal and oral microbiome but a significant overlap between the microbe composition of the oral cavity and the lungs [98]. The existence of a diverse and compositionally different microbiota in the upper airways along with interactions with the intestinal microbiome suggests a more detailed characterisation of mucosal immune homeostasis may be necessary to understand the pathogenesis of URS in athletes.

6 Integrated Immune-Microbial Biomarker Profiling: A Systems Approach

Athlete-related URS appears to be a heterogeneous condition with a complex pathophysiology encompassing an interaction between the immune system, microbial elements and environmental factors. Traditionally, immune profiling in exercise immunology and across other disciplines has focused on the analysis of single or a limited set of immunological parameters. The mucosal immune system includes a wide array of cells, humoural factors and mechanical barriers, the nature of its activation is multifactorial and transient, and its constituents share overlapping functions that may be redundant, antagonistic or synergistic within regulatory cascades (Fig. 2). While immune phenotype is traditionally measured at the proteomic level, the plasticity and adaptability of immune activity is governed by molecular transcriptional and translational regulation and post-translational modifications [99, 100]. In many cases, the correlation between molecular immune activity and protein abundance is poor, indicating that the dynamic nature of immune regulation is not linear and, in many cases, uncoupled with the measured phenotype [101]. The complexity of the immune system working across several levels therefore requires the integration of molecular, phenotypic and behavioural data to identify regulatory networks that govern homeostasis and identify critical molecules driving aberrant inflammatory activity [102].

The use of ‘omics’ technology to evaluate immune status in a holistic manner, including metabolites (metabolomics), proteins (proteomics), messenger RNA (transcriptomics) or genes (genomics), and metagenomics (microbiota) [103] is providing unprecedented insight into the ‘immunopathology’ of disease. New technologies, such as the nCounter® Analysis System (NanoString...
Technologies, Inc., Seattle, WA, USA) that utilise small sample volumes provide the opportunity to undertake simultaneous immune genome and phenotype analyses. Mass cytometry for immune cell phenotyping overcomes the limitations of flow cytometry spectral overlap that restricts routine cell phenotyping to 8–12 immune markers. Mass cytometry allows for the simultaneous quantitation of 30–40 cell markers, which provides the opportunity to interrogate multiple cell types and signalling pathways for a more holistic understanding of biological function [104]. The ability to simultaneously characterise genomic and proteomic factors is revealing biomarkers that are being used for diagnostic purposes and the stratification of patients into disease risk groups [105, 106]. In the sports medicine setting, the use of genomic and proteomic analyses would extend traditional cell phenotyping to include functional assessment and provide important information on changes in immune capability that may underpin URS.

The generation of large biological datasets is recognised to pose substantial challenges in relation to data analysis and interpretation. Integration of large data sets from high-throughput technology requires the use of systems biology and machine learning approaches (Fig. 3). These approaches aim to build models of biological systems that incorporate interactions between genome, metagenome and the environment. Systems biology has shown promise in cancer, vaccine development, gastroenterology and in understanding inflammation in ageing [102, 107–109]. Our group has used these approaches to highlight the utility of using intestinal permeability measures as a tool for predicting type 2 diabetes mellitus risk [110]. Furthermore, the use of omics biomarker profiling is showing value for the identification of predictive markers in cancer settings [111]. Sports medicine is likely to be one of the next frontiers to move beyond the conventional focus of examining discrete targets for diagnostic and therapeutic purposes and embrace systems approaches for athlete health and performance. Integration of sequencing and high-throughput technologies using computational biology modelling approaches may provide important information on how perturbations in immune, microbial or environmental factors can lead to URS in athletes.

7 Future Directions

In recent years, the advancement, affordability and availability of high-throughput analytical methods has increased substantially. High-throughput methods are being applied to a broad range of research questions to reveal highly detailed information about the complex biological interactions underpinning disease [112, 113]. These developments are facilitating the search for biomarkers used to monitor, predict and identify disease and pathophysiological processes. As a discipline, there is a long history in exercise immunology of examining the effects of exercise on salivary proteins given the ease of saliva collection [114, 115]. In-vivo studies utilising micro-proteomics technology for salivary assessment between athletes that experience URS compared with those who do not experience URS may reveal key molecules that alter susceptibility to URS. Furthermore, the use of micro-proteomics in nasal secretions would also offer new strategies to understand URS in athletes. Traditionally, large secretion volumes are required from healthy individuals for analysis of nasal proteins, which would be overcome through the use of micro-proteomics. Identification of new immune proteins in secretions of the airways would provide biomarker targets for assessment in exercise-induced suppression and URS.

The airway microbiome (nose, mouth and respiratory tract) represents an intriguing research area for exercise immunology. Given the various dietary practices of endurance vs. team sport athletes, and weight-restricted athletes, there is a unique opportunity to examine the role of dietary practices and exercise on the composition of both the intestinal and airway microbiome. Follow-up studies are then needed to examine whether changes in the composition modify mucosal immune control and susceptibility to URS. Furthermore, whether modification of the airway microbiome might reduce susceptibility to URS in the same manner that faecal transplants have altered disease outcomes in the colon is a tantalising prospect. Early-phase studies for the use of topical nasal sprays for URTI by modifying the nasal microbiota are well tolerated and safe in healthy adults [116], suggesting that therapies targeting the airway microbiota for URS are under consideration. While not yet conclusive, the consumption of probiotics has shown efficacy for URS and gastrointestinal illness in athletes. Intriguingly, there are few studies characterising the intestinal microbiota in athletes [73]. Research in gut microbiota is moving beyond just characterisation of phyla towards an understanding of structure function for targeted manipulation to elicit specific health benefits [117]. Future work to examine the effect of acute and chronic exercise on microbes of the gut might identify exercise- or sport-specific alterations in individual bacterial phyla, such as butyrate producers, that permit implementation of personalised probiotic regimens.

Deciphering aberrant processes in the mucosal immune system that denote dysfunction or altered susceptibility to infection requires a schema for the intricate balance between airway homeostasis and inflammation. Omics technology and use of approaches such as systems biology to integrate and construct multi-dimensional regulatory networks may shed light on the immunopathology
underpinning URS. There is a need to undertake simultaneous molecular and protein phenotyping from mucosal and systemic samples to gain a better insight into immune status and to determine the relevance of sampling from one site for insight into the status of another. This type of work needs to examine whether rare immune cell populations co-exist and whether they exhibit similar functional capacity [118]. Such approaches may identify combinations of biomarkers that more accurately allow for earlier diagnosis of dysregulation at mucosal surfaces or increased susceptibility to URS. Within the context of elite athletes, biomarkers associated with URS could be used within the clinic to flag at-risk athletes who may benefit from closer assessment and intervention. The biomarkers could also be used to monitor athletes’ responses to training, dietary or therapeutics intervention and to optimise illness treatment.

8 Conclusions

Upper respiratory symptoms may have a negative impact on athletes in heavy training or during competition by altering psychological and/or physiological capacity. The differential diagnoses of URS in athletic settings imply that mucosal immune dysregulation may underpin a substantial number of cases of URS. Maintenance of homeostasis in the respiratory tract involves complex immune, microbial and environmental interaction. Supplements that modify gut bacteria, including probiotics and prebiotics, are popular with athletes at all levels and a better understanding of the effects of exercise on the microbiota may lead to more personalised and effective supplement regimes. Identifying the role of the oral microbiome in URS and whether these microbes can be manipulated is a promising area of
research. Use of new technology and data approaches in studies combined with clinical outcomes will provide a better understanding of the relationship between exercise and the mucosal immune system in URS. Improved understanding of this relationship will lead to nutrition and training strategies to improve gut and immune function and reduce the impact of URS on athletes.

Acknowledgements The authors thank Ms Corinna Bennett for her assistance with Fig. 1.

Compliance with Ethical Standards

Funding This article was published in a supplement supported by the Gatorade Sports Science Institute (GSSI). The supplement was guest edited by Lawrence L. Spriet who attended a meeting of the GSSI expert panel in October 2016 and received honoraria from the GSSI for his participation in the meeting and the writing of a manuscript. He received no honoraria for guest editing the supplement. Dr. Spriet selected peer reviewers for each paper and managed the process, except for his own paper. Nicholas P. West also attended the meeting of the GSSI expert panel in October 2016 and received an honorarium from the GSSI, a division of PepsiCo, Inc. for his participation in the meeting and the writing of this manuscript. The views expressed in this manuscript are those of the authors and do not necessarily reflect the position or policy of PepsiCo, Inc.

Conflict of interest The authors are recipients of industry Grants for research related to probiotics and gut health.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Engebretsen L, Soligard T, Steffen K, et al. Sports injuries and illnesses during the London Summer Olympic Games 2012. Br J Sports Med. 2013;47:407–14.
2. Engebretsen L, Steffen K, Alonso JM, et al. Sports injuries and illnesses during the Winter Olympic Games 2010. Br J Sports Med. 2010;44:772–80.
3. Palmer-Green D, Elliott N. Sports injury and illness epidemiology: Great Britain Olympic Team (TeamGB) surveillance during the Sochi 2014 Winter Olympic Games. Br J Sports Med. 2014;49:25–9.
4. Gleeson M, Pyne DB. Respiratory inflammation and infections in high-performance athletes. Immunol Cell Biol. 2016;94:124–31.
5. Pyne DB, McDonald WA, Gleeson M, et al. Mucosal immunity, respiratory illness, and competitive performance in elite swimmers. Med Sci Sports Exerc. 2001;33:348–53.
6. Smith A. A review of the effects of colds and influenza on human performance. J Soc Occup Med. 1989;39:65–8.
7. Smith A, Thomas M, Kent J, et al. Effects of the common cold on mood and performance. Psychoneuroendocrinology. 1998;23:733–9.
8. Smith AP. Effects of the common cold on mood, psychomotor performance, the encoding of new information, speed of working memory and semantic processing. Brain Behav Immun. 2012;26:1072–6.
9. Pyne DB, Hopkins WG, Batterham AM, et al. Characterising the individual performance responses to mild illness in international swimmers. Br J Sports Med. 2005;39:752–6.
10. Fricker PA, Pyne DB, Saunders PU, et al. Influence of training loads on patterns of illness in elite distance runners. Clin J Sport Med. 2005;15:246–52.
11. Nieman DC, Nehlsen-Cannarella SL, Fagoga OR, et al. Immune function in female elite rowers and non-athletes. Br J Sports Med. 2000;34:181–7.
12. Mossad SB. Upper respiratory tract infections. Cleveland (OH): Cleveland Clinic, Department of Infectious Disease; 2011.
13. Slater G, Tan B, Teh KC. Dietary supplementation practices of Singaporean athletes. Int J Sport Nutr Exerc Metab. 2003;13:320–32.
14. Drew M, Vlahovich N, Hughes D, et al. Prevalence of illness, poor mental health and sleep quality and low energy availability prior to the 2016 Summer Olympic Games. Br J Sports Med. 2017. https://doi.org/10.1136/bjsports-2017-098208 (Epub ahead of print).
15. Moreira A, Delgado L, Moreira P, et al. Does exercise increase the risk of upper respiratory tract infections? Br Med Bull. 2009;90:111–31.
16. Malm C. Susceptibility to infections in elite athletes: the S-curve. Scand J Med Sci Sports. 2006;16:4–6.
17. Nieman DC. Immune response to heavy exertion. J Appl Physiol. 1997;82:1385–94.
18. Nieman DC, Johanssen LM, Lee JW. Infectious episodes in runners before and after a roadrace. J Sports Med Phys Fit. 1989;29:289–96.
19. Nieman DC, Johanssen LM, Lee JW, et al. Infectious episodes in runners before and after the Los Angeles Marathon. J Sports Med Phys Fit. 1990;30:316–28.
20. Witard OC, Turner JE, Jackman SR, et al. High dietary protein restores overreaching induced impairments in leukocyte trafficking and reduces the incidence of upper respiratory tract infection in elite cyclists. Brain Behav Immun. 2014;39:211–9.
21. Spence L, Brown WJ, Pyne DB, et al. Incidence, etiology, and symptomatology of upper respiratory illness in elite athletes. Med Sci Sports Exerc. 2007;39:573–86.
22. Cox AJ, Gleeson M, Pyne DB, et al. Clinical and laboratory evaluation of upper respiratory symptoms in elite athletes. Clin J Sport Med. 2008;18:438–45.
23. Wurzel DF, Marchant JM, Clark JE, et al. Respiratory virus detection in nasopharyngeal aspirate versus bronchoalveolar lavage is dependent on virus type in children with chronic respiratory symptoms. J Clin Virol. 2013;58:683–8.
24. Bonsignore MR, Morici G, Riccobono L, et al. Airway inflammation in nonathletic amateur runners. Am J Physiol. 2001;281:L668–76.
25. Bonsignore MR, Morici G, Vignola AM, et al. Increased airway inflammatory cells in endurance athletes: what do they mean? Clin Exp Allergy. 2003;33:14–21.
26. Anderson SD, Holzer K. Exercise-induced asthma: is it the right diagnosis in elite athletes? J Allergy Clin Immunol. 2000;106:419–28.
27. Bonini M, Palange P. Exercise-induced bronchoconstriction: new evidence in pathogenesis, diagnosis and treatment. Asthma Res Pract. 2015;1:1.
28. Walsh NP, Oliver SJ. Exercise, immune function and respiratory infection: an update on the influence of training and environmental stress. Immunol Cell Biol. 2016;94:132–9.

Springer
29. Yosef N, Regev A. Writ large: genomic dissection of the effect of cellular environment on immune response. Science. 2016;354:64–8.
30. Raz E. Organ-specific regulation of innate immunity. Nat Immunol. 2007;8:3–4.
31. Weitnauer M, Mijósek V, Dalpke A. Control of local immunity by airway epithelial cells. Mucosal Immunol. 2016;9:287–98.
32. Ballke C, Gran E, Baekkevold ES, et al. Characterization of regulatory T-cell markers in CD4+ T cells of the upper airway mucosa. PLoS One. 2016;11:e0148826.
33. Hirota K, Turner J-E, Villa M, et al. Plasticity of Th17 cells in Peyer’s patches is responsible for the induction of T cell-dependent IgA responses. Nat Immunol. 2013;14:372–9.
34. Koues OI, Collins PL, Cella M, et al. Distinct gene regulatory pathways for human innate versus adaptive lymphoid cells. Cell. 2016;165:1134–46.
35. Kippelen P, Fitch KD, Anderson SD, et al. Respiratory health of elite athletes: preventing airway injury: a critical review. Br J Sports Med. 2012;46:471–6.
36. Morita H, Arae K, Unno H, et al. An interleukin-33-mast cell-interleukin-2 axis suppresses papain-induced allergic inflammation by promoting regulatory T cell numbers. Immunity. 2015;43:175–86.
37. Hallstrand TS, Hackett TL, Altemeier WA, et al. Airway epithelial regulation of pulmonary immune homeostasis and inflammation. Clin Immunol. 2014;151:1–15.
38. Smith LL. Overtraining, excessive exercise, and altered immunity. Sports Med. 2003;33:347–64.
39. West NP, Pyne DB, Kyd JM, et al. The effect of exercise on innate mucosal immunity. Br J Sports Med. 2010;44:227–31.
40. Gleeson M, Pyne DB. Special feature for the Olympics: effects of exercise on the immune system: exercise effects on mucosal immunity. Immunol Cell Biol. 2000;78:536–44.
41. Walsh NP, Gleeson M, Shephard RJ, et al. Position statement. Part one: immune function and exercise. Exerc Immunol Rev. 2011;17:6–63.
42. Francis JL, Gleeson M, Pyne DB, et al. Variation of salivary immunoglobulins in exercising and sedentary populations. Med Sci Sports Exerc. 2005;37:571–8.
43. Marion T, Elbahesh H, Thomas PG, et al. Respiratory mucosal proteome quantification in human influenza infections. PLoS One. 2016;11:e0153674.
44. Kelster MM, Holm A, Pedersen C. Plasma cytokines, coxin, MIP-1α, MCP-4, and vascular endothelial growth factor in acute lower respiratory tract infection. APMIS. 2016;125:148–56.
45. Brestoff JR, Kim BS, Saenz SA, et al. Group 2 innate lymphoid cells promote beiging of white adipose tissue and limit obesity. Nature. 2015;519:242–6.
46. Wiktorowicz JE, Soman KV. Discovery of candidate biomarkers. Adv Exp Med Biol. 2016;919:443–62.
47. West NP, Horn PL, Pyne DB, et al. Probiotic supplementation has little effect on peripheral blood regulatory T cells. J Allergy Clin Immunol. 2016;138:1749–52.
48. Weinhold M, Shimabukuro-Vornhagen A, Franke A, et al. Physical exercise modulates the homeostasis of human regulatory T cells. J Allergy Clin Immunol. 2016;137:1607–10.
49. Gleeson M, Bishop NC, Stensel DJ, et al. The anti-inflammatory effects of exercise: mechanisms and implications for the prevention and treatment of disease. Nat Rev Immunol. 2011;11:607–15.
50. Simpson RJ, Kunz H, Agha N, et al. Exercise and the regulation of immune functions. Progr Mol Biol Transl Sci. 2015;135:355–80.
51. Sznurkowska K, Żawrocki A, Sznurkowski J, et al. Peripheral and intestinal T-regulatory cells are upregulated in children with inflammatory bowel disease at onset of disease. Immunol Invest. 2016;45:787–96.
52. Godfrey DI, Ulrich AP, McCluskey J, et al. The burgeoning family of unconventional T cells. Nat Immunol. 2015;16:1114–23.
53. Moldaver DM, Larché M, Rudulier CD. An update on lymphocyte subtypes in asthma and airway disease. Chest J. 2016;151:1122–30.
54. Berker M, Frank LJ, Geßner AL, et al. Allergies: a T cells perspective in the era beyond the TH1/TH2 paradigm. Clin Immunol. 2017;174:73–83.
55. Ursell LK, Haaser HJ, Van Treuren V, et al. The intestinal metabolome: an intersection between microbiota and host. Gastroenterology. 2014;146:1470–6.
56. Putignani L, Del Chierico F, Petrucca A, et al. The human gut microbiota: a dynamic interplay with the host from birth to senescence settled during childhood. Pediatr Res. 2014;76:2–10.
57. Cox AJ, West NP, Cripps AW. Obesity, inflammation, and the gut microbiota. Lancet Diab Endocrinol. 2015;3:207–15.
58. Turbaugh PJ, Ley RE, Hamady M, et al. The human microbiome project: exploring the microbial part of ourselves in a changing world. Nature. 2007;449:804–10.
59. Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature. 2012;486:207–14.
60. Kang W, Kudsk KA. Is there evidence that the gut contributes to mucosal immunity in humans? J Parenter Enter Nutr. 2007;31:245–58.
61. Gallichan WS, Woolstencroft RN, Guarasci T, et al. Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract. J Immunol. 2001;166:3451–7.
62. Cerutti A. The regulation of IgA class switching. Nat Rev Immunol. 2000;8:421–34.
63. Samuelson DR, Welsh DA, Shellito JE. Regulation of lung immunity and host defense by the intestinal microbiota. Front Microbiol. 2015;6:1085.
64. Gareau MG, Sherman PM, Walker WA. Probiotics and the gut microbiota in intestinal health and disease. Nat Rev Gastroenterol Hepatol. 2010;7:503–14.
65. Cortesby B. Multi-faceted functions of secretory IgA at mucosal surfaces. Front Immunol. 2013;4:185.
66. Osumu R, Takeda K. Maintenance of gut homeostasis by the mucosal immune system. Proc Jpn Acad Ser B. 2016;92:423–35.
67. Atarashi K, Tanoue T, Shima T, et al. Induction of colonic regulatory T cells by indigenous Clostridium species. Science. 2011;331:337–41.
68. Ohnmaech C, Park J-H, Cording S, et al. The microbiota regulates type 2 immunity through RORγt+ T cells. Science. 2015;349:989–93.
69. Lamb AL, Hess DE, Edenborn S, et al. Elevated salivary IgA decreased anxiety, and an altered oral microbiota are associated with active participation on an undergraduate athletic team. Physiol Behav. 2016;169:169–77.
70. Tims S. Mining microbiota signatures in human intestinal tract metagenomes. Wageningen: Wageningen University; 2016.
71. Clarke SF, Murphy EF, O'Sullivan O, et al. The intestinal microbiota: a dynamic interplay with the host from birth to senescence settled during childhood. J Allergy Clin Immunol. 2016;138:1749–52.
74. Estaki M, Pither J, Baumeister P, et al. Cardiorespiratory fitness as a predictor of intestinal microbial diversity and distinct metagenomic functions. Microbiome. 2016;4(1):42.
75. Kekkonen RA, Vasankari TJ, Vuorimaa T, et al. The effect of probiotics on respiratory infections and gastrointestinal symptoms during training in marathon runners. Int J Sport Nutr Exerc Metab. 2007;17:352–63.
76. Gleeson M, Bishop NC, Oliveira M, et al. Effects of a *Lactobacillus fermentum* probiotic intervention on infection, cold symptom duration and severity, and mucosal immunity in endurance athletes. Int J Sport Nutr Exerc Metab. 2012;22:235–42.
77. West NP, Pyne DB, Peake JM, et al. Probiotics, immunity and exercise: a review. Exerc Immunol Rev. 2009;15:107–26.
78. West NP, Pyne DB, Criggs AW, et al. *Lactobacillus fermentum* (PCC(R)) supplementation and gastrointestinal and respiratory-tract illness symptoms: a randomised control trial in athletes. Nutr J. 2011;10:1.
79. Gleeson M, Bishop NC, Oliveira M, et al. Daily probiotic’s (*Lactobacillus casei* Shirata) reduction of infection incidence in athletes. Int J Sport Nutr Exerc Metab. 2011;21:55–64.
80. Mack DR, Ahrne S, Hyde L, et al. Extracellular MUC3 mucin secretion follows adherence of Lactobacillus strains to intestinal epithelial cells in vitro. Gut. 2003;52:827–33.
81. McFarlin BK, Carpenter KC, Davidson T, et al. Baker’s yeast beta glucan supplementation increases salivary IgA and decreases cold/flu symptomatic days after intense exercise. J Diet Suppl. 2013;10:171–83.
82. Bergendiova K, Tibenska E, Majtan J. Pleuran (Pleurotus ostreatus) supplementation, cellular immune response and respiratory tract infections in athletes. Eur J Appl Physiol. 2011;111:2033–40.
83. Niemen DC, Henson D, McMahon M, et al. B-glucan, immune function, and upper respiratory tract infections in athletes. Med Sci Sports Exerc. 2008;40:1463–71.
84. West NP, Christophersen CT, Pyne DB, et al. Butyrylated starch increases colonic butyrate concentration but has limited effects on immunity in healthy physically active individuals. Exerc Immunol Rev. 2013;19:102–19.
85. Miquel S, Martin R, Rossi O, et al. *Faecalibacterium prausnitzii* and human intestinal health. Curr Opin Microbiol. 2013;16:235–61.
86. Haywood BA, Black KE, Baker D, et al. Probiotic supplementation reduces the duration and incidence of infections but not severity in elite rugby union players. J Sci Med Sport. 2014;17:356–60.
87. West NP, Pyne DB, Criggs AW, et al. *Lactobacillus fermentum* (PCC(R)) supplementation and gastrointestinal and respiratory-tract illness symptoms: a randomised control trial in athletes. Nutr J. 2011;10:30.
88. West NP, Horn PL, Pyne DB, et al. Probiotic supplementation for respiratory and gastrointestinal illness symptoms in healthy physically active individuals. Clin Nutr. 2014;33:581–7.
89. Davison G, Marchbank T, March DS, et al. Zinc carnosine works with bovine colostrum in truncating heavy exercise-induced increase in gut permeability in healthy volunteers. Am J Clin Nutr. 2016;104:526–36.
90. Morrison SA, Cheung SS, Cotter JD. Bovine colostrum, training status, and gastrointestinal permeability during exercise in the heat: a placebo-controlled double-blind study. Appl Physiol Nutr Metab. 2014;39:1070–82.
91. Buckley JD, Butler RN, Southcott E, et al. Bovine colostrum supplementation during running training increases intestinal permeability. Nutrients. 2009;1:224–34.
92. Jones AW, March DS, Curtis F, et al. Bovine colostrum supplementation and upper respiratory symptoms during exercise training: a systematic review and meta-analysis of randomised controlled trials. BMC Sports Sci Med Rehab. 2016;8:21.
93. Gleeson M. Immunological aspects of sport nutrition. Immunol Cell Biol. 2015;94:117–23.
94. Wade WG. The oral microbiome in health and disease. Pharmacol Res. 2013;69:137–43.
95. Grassl N, Kulak NA, Pichler G, et al. Ultra-deep and quantitative saliva proteome reveals dynamics of the oral microbiome. Genome Med. 2016;8:1.
96. Zhang Q, Cox M, Liang Z, et al. Airway microbiota in severe asthma and relationship to asthma severity and phenotypes. PLoS One. 2016;11:e0152724.
97. McLean JS. Advancements toward a systems level understanding of the human oral microbiome. Front Cell Infect Microbiol. 2014;4:98.
98. Bassis CM, Erb-Downward JR, Dickson RP, et al. Analysis of the upper respiratory tract microbiotas as the source of the lung and gastric microbiotas in healthy individuals. MBio. 2015;6:e00037.
99. Liu J, Qian C, Cao X. Post-translational modification control of innate immunity. Immunity. 2016;45:15–30.
100. Isaacs SR, Wang J, Kim KW, et al. MicroRNAs in type 1 diabetes: complex interregulation of the immune system, β cell function and viral infections. Curr Diab Rep. 2016;16:133.
101. Maier T, Giell M, Serrano L. Correlation of mRNA and protein in complex biological samples. FEBS Lett. 2009;583:3966–73.
102. Zhao Y, Forst CV, Sayegh CE, et al. Molecular and genetic inflammation networks in major human diseases. Mol BioSyst. 2016;12:2318–41.
103. Horgan RP, Kenny LC. ‘Omics’ technologies: genomics, transcriptomics, proteomics and metabolomics. Obstet Gynaecol. 2011;13:189–95.
104. Baumgart S, Peddinghaus A, Schulte-Wrede U, et al. OMIP-034: comprehensive immune phenotyping of human peripheral leukocytes by mass cytometry for monitoring immunomodulatory therapies. Cytom Part A. 2017;91:25–33.
105. Santos G, Nikolov S, Lai X, et al. Model-based genotype-phenotype mapping used to investigate gene signatures of immune sensitivity and resistance in melanoma micrometastasis. Sci Rep. 2016;6:24967.
106. Dobbin KK, Cesano A, Alvarez J, et al. Validation of biomarkers to predict response to immunotherapy in cancer. In: Volume II: clinical validation and regulatory considerations. J Immunother Cancer. 2016;4:77.
107. Wooden B, Goossens N, Hoshida Y, et al. Using big data to discover diagnostics and therapeutics for gastrointestinal and liver diseases. Gastroenterology. 2017;152:53–67.
108. Eralp Y. The role of genomic profiling in advanced breast cancer: the two faces of Janus. Transl Oncogenomics. 2016;8:1.
109. Mooney KM, Morgan AE, Mc Auley MT. Aging and computational systems biology. Wiley Interdiscip Rev Syst Biol Med. 2016;8:123–39.
110. Cox A, Zhang P, Bowden D, et al. Increased intestinal permeability as a risk factor for type 2 diabetes. Diab Metab. 2017;43:163–6.
111. Walden B, Storhoff J, Nielsen T, et al. Development and verification of the PAM50-based Prosigna breast cancer gene signature assay. BMC Med Genom. 2015;8:1.
112. Wistuba-Hamprecht K, Martens A, Weide B, et al. Establishing high dimensional immune signatures from peripheral blood via mass cytometry in a discovery cohort of stage IV melanoma patients. J Immunol. 2017;198(2):927–36.
113. Walter RFH, Vollbrecht C, Christoph D, et al. Massive parallel sequencing and digital gene expression analysis reveals potential mechanisms to overcome therapy resistance in pulmonary neuroendocrine tumors. J Cancer. 2016;7:2165–72.
114. Macdonald L, Bellinger P, Minahan C. Reliability of salivary cortisol and immunoglobulin-A measurements from the IPRO® before and after sprint cycling exercise. J Sports Med Phys Fit. 2017;57(12):1680–6.

115. Lindsay A, Costello JT. Realising the potential of urine and saliva as diagnostic tools in sport and exercise medicine. Sports Med. 2017;47:11–31.

116. Santagati M, Scillato M, Muscaridola N, et al. Colonization, safety, and tolerability study of the Streptococcus salivarius 24SMBc nasal spray for its application in upper respiratory tract infections. Eur J Clin Microbiol Infect Dis. 2015;34:2075–80.

117. Reigstad CS, Kashyap PC. Beyond phylotyping: understanding the impact of gut microbiota on host biology. Neurogastroenterol Motil. 2013;25:358–72.

118. Rempala GA, Seweryn M. Methods for diversity and overlap analysis in T-cell receptor populations. J Math Biol. 2013;67:1339–68.

119. Clancy RL, Gleeson M, Cox A, et al. Reversal in fatigued athletes of a defect in interferon gamma secretion after administration of Lactobacillus acidophilus. Br J Sports Med. 2006;40:351–4.

120. Cox AJ, Pyne DB, Saunders PU, et al. Oral administration of the probiotic Lactobacillus fermentum VRI-003 and mucosal immunity in endurance athletes. Br J Sports Med. 2010;44(4):222–6.